The final in a series on the need to formally prioritise patient input in HTA decision-making, we argue that the system currently lacks the ethical framework necessary to make morally defensible decisions. No system of decision-making can be considered ethical when its rules, when properly applied, lead to outcomes that delay access to treatment with consequent suffering, harm, and in some cases, death.
If the system properly applied results in harm, then the problem is worse than we think
November 20, 2025 Latest NewsBioPharmaCommentNews of the Day
Latest Video
New Stories
-
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech -
Health Department clarifies PBAC plan after confusion over paediatric access to biologics
December 10, 2025 - - Latest News -
If this was the plan, why wasn't it included in the response to questions last week?
December 10, 2025 - - Latest News -
Immutep strikes major licensing deal with Dr. Reddy’s to commercialise novel cancer immunotherapy
December 9, 2025 - - Australian Biotech
